Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ClinicalTrials.gov 24,857 recruiting now free trial finder

Find a clinical trial that's recruiting now

Search 24,857 actively recruiting US clinical trials by condition, drug, or state, each entry links straight to its NIH ClinicalTrials.gov record so you can check eligibility and contact the study team.

24,857
trials recruiting now
14%
of all US trials open to enrollment
52
states with recruiting sites

A trial is listed as recruiting when its sponsor has marked it open to new participants on the public registry. Type a condition or drug name (for example, "breast cancer" or "pembrolizumab") to narrow the list, and add a state to find studies with a site near you. Results are ordered with the most relevant recruiting studies first; each card shows the study phase and enrollment target, and opens the full record, including eligibility criteria and contact details, on ClinicalTrials.gov.

Showing the 40 largest recruiting trials by target enrollment in Idaho. Use the search field to focus on a condition or drug.

Recruiting Phase 3 11,000 participants

EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)

Boehringer Ingelheim

NCT06531824

Recruiting Phase 3 6,000 participants

BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies

Pfizer

NCT07160244

Recruiting Phase 3 5,200 participants

A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients

Colorado Prevention Center

NCT06008197

Recruiting 5,000 participants

Deep Brain Stimulation (DBS) Retrospective Outcomes Study

Boston Scientific Corporation

NCT03664609

Recruiting 5,000 participants

The Society for Obstetric Anesthesia and Perinatology Research Network General Anesthesia Registry

Yale University

NCT06030063

Recruiting NA 4,000 participants

The Fourth Left Atrial Appendage Occlusion Study

Hamilton Health Sciences Corporation

NCT05963698

Recruiting NA 4,000 participants

Staged Complete Revascularization for Coronary Artery Disease vs Medical Management Alone in Patients With AS Undergoing Transcatheter Aortic Valve Replacement

University of British Columbia

NCT04634240

Recruiting 3,000 participants

Specimen Collection from Patients with Non-Hematologic Cancer for Use in Development of a Liquid Biopsy Assay

Sequenom

NCT02586389

Recruiting NA 2,250 participants

PROGRESS: Management of Moderate Aortic Stenosis by Clinical Surveillance or TAVR

Edwards Lifesciences

NCT04889872

Recruiting 2,000 participants

ASSESS ALL ALS Study

St. Joseph's Hospital and Medical Center, Phoenix

NCT06578195

Recruiting Phase 3 1,900 participants

REVEAL Study - Diagnostic Testing for PTSD Using the Senseye Diagnostic Tool

Senseye

NCT07280065

Recruiting Phase 4 1,710 participants

LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women

Insud Pharma

NCT05303636

Recruiting 1,500 participants

Intracept Minimally-invasive PROcedure for VErtebrogenic Back Pain

Boston Scientific Corporation

NCT06827262

Recruiting 1,500 participants

Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry

Boston Scientific Corporation

NCT02071134

Recruiting Phase 1 1,405 participants

Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age

ModernaTX

NCT05992935

Recruiting Phase 2 1,217 participants

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

Eli Lilly and Company

NCT06143956

Recruiting Phase 3 1,200 participants

A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes

Eli Lilly and Company

NCT06993792

Recruiting Phase 3 1,095 participants

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

Genmab

NCT06191744

Recruiting 1,000 participants

Minimal Residual Disease Assessment in Patients With Colorectal Cancer, the MiRDA-C Study

M.D. Anderson Cancer Center

NCT04739072

Recruiting NA 1,000 participants

First Face Training Evaluation in Tribal Communities

Cambridge Health Alliance

NCT05998005

Recruiting Phase 3 1,000 participants

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

Merck Sharp & Dohme

NCT06841354

Recruiting Phase 3 970 participants

Extracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS)

Direct Biologics

NCT05354141

Recruiting Phase 2 920 participants

Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

Hoffmann-La Roche

NCT04589845

Recruiting 900 participants

A US Non-interventional, Effectiveness and Safety Study of Patients Treated With SKYTROFA

Ascendis Pharma Endocrinology Division A/S

NCT05820672

Recruiting Phase 2 900 participants

Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

SWOG Cancer Research Network

NCT06769126

Recruiting Phase 3 900 participants

A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age

GlaxoSmithKline

NCT06855160

Recruiting Phase 3 880 participants

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

AstraZeneca

NCT06692738

Recruiting Phase 3 868 participants

A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

Merck Sharp & Dohme

NCT06077760

Recruiting Phase 3 795 participants

A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide

Janssen Research & Development

NCT06208150

Recruiting Phase 3 750 participants

A Surveillance Study of Susceptibility to Baloxavir Marboxil in Pediatric Participants With Influenza and Transmission of Influenza to Household Contacts

Hoffmann-La Roche

NCT06094010

Recruiting Phase 4 730 participants

Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study

Chris Goss

NCT05548283

Recruiting Phase 3 723 participants

A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes

Sanofi

NCT07088068

Recruiting Phase 3 723 participants

A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine

Pfizer

NCT06641466

Recruiting NA 699 participants

A Global Study Comparing Pulsed Field Ablation With Electrographic Flow Mapping Versus Posterior Wall Ablation for Persistent Atrial Fibrillation

Boston Scientific Corporation

NCT07187115

Recruiting Phase 3 680 participants

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

Merck Sharp & Dohme

NCT06623422

Recruiting Phase 3 675 participants

A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis

AbbVie

NCT06461897

Recruiting Phase 3 640 participants

Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects

Pfizer

NCT05156398

Recruiting Phase 3 620 participants

Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer

AstraZeneca

NCT06467357

Recruiting Phase 2 600 participants

JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record)

PPD Development

NCT06703073

Recruiting Phase 3 600 participants

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Hoffmann-La Roche

NCT06793215

Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Recruiting status is reported by each study's sponsor and mirrored from the public registry. Always confirm current eligibility and status on ClinicalTrials.gov before contacting a study.

Verify with NIH →